Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) and Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) are both listed in the Medicinal Chemicals and Botanical Products industry. Sun Pharmaceutical Industries has a market capitalisation of ₹4,24,682 Cr and Zydus Lifesciences ₹1,23,740 Cr, as of 9 Nov 2026. Their P/E ratios are 37 and 24.8 respectively. Return on equity is 14.72% for Sun Pharmaceutical Industries and 18.32% for Zydus Lifesciences. Over one year, Sun Pharmaceutical Industries's share price is up 11.6% and Zydus Lifesciences's is up 23.9%.
| Metric | Sun Pharmaceutical Industries | Zydus Lifesciences |
|---|---|---|
| NSE Symbol | SUNPHARMA | ZYDUSLIFE |
| BSE Code | 524715 | 532321 |
| Share Price | ₹1,909.20 | ₹1,215.90 |
| Market Cap | ₹4,24,682 Cr | ₹1,23,740 Cr |
| P/E Ratio | 37 | 24.8 |
| Return on Equity | 14.72% | 18.32% |
| Return on Assets | 8.47% | 8.13% |
| Dividend Yield | 0.56% | 0.08% |
| Beta (1Y) | -0.15 | 0.24 |
| 1-Year Price Change | +11.6% | +23.9% |
| 3-Month Price Change | -2.1% | +8.7% |
| 52-Week Range | ₹1,583.70 – ₹2,046.90 | ₹835.50 – ₹1,266.60 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹16,199 Cr | ₹7,910 Cr |
| Quarterly Net Profit | ₹1,995 Cr | ₹928 Cr |
| Net Margin | 12.3% | 11.7% |
| EPS (Basic, Quarter) | ₹8.30 | ₹9.28 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Ahmedabad, Gujarat |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides g…
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of onco…
Sun Pharmaceutical Industries has a market capitalisation of ₹4,24,682 Cr, against ₹1,23,740 Cr for Zydus Lifesciences as of 9 Nov 2026, about 3.4 times the size by market cap.
Sun Pharmaceutical Industries has a P/E of 37 and Zydus Lifesciences a P/E of 24.8 as of 9 Nov 2026.
Sun Pharmaceutical Industries has a return on equity of 14.72% and Zydus Lifesciences 18.32%.
Sun Pharmaceutical Industries's share price is up 11.6% over one year and Zydus Lifesciences's is up 23.9%.
Sun Pharmaceutical Industries reported revenue of ₹16,199 Cr and net profit of ₹1,995 Cr for Q2 FY27. Zydus Lifesciences reported revenue of ₹7,910 Cr and net profit of ₹928 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.